370 related articles for article (PubMed ID: 29717036)
21. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
Blauvelt A; Reich K; Lebwohl M; Burge D; Arendt C; Peterson L; Drew J; Rolleri R; Gottlieb AB
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):546-552. PubMed ID: 30242918
[TBL] [Abstract][Full Text] [Related]
22. Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol.
Navarro Ruiz A; Toledo Alberola F; Aceituno S;
Farm Hosp; 2024; 48(2):51-56. PubMed ID: 37739901
[TBL] [Abstract][Full Text] [Related]
23. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
24. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
van der Heijde D; Fleischmann R; Wollenhaupt J; Deodhar A; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; Mease PJ
Ann Rheum Dis; 2014 Jan; 73(1):233-7. PubMed ID: 23942869
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.
Umezawa Y; Asahina A; Imafuku S; Tada Y; Sano S; Morita A; Sakurai S; Hoshii N; Tilt N; Nakagawa H
Dermatol Ther (Heidelb); 2021 Jun; 11(3):943-960. PubMed ID: 33886085
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of certolizumab pegol in naïve versus multi-treated patients affected by psoriatic arthritis.
Dattola A; Vollono L; Cannizzaro MV; Caposiena Caro RD; Mazzilli S; Melino G; Candi E; Campione E; Bianchi L
Ital J Dermatol Venerol; 2021 Aug; 156(4):434-439. PubMed ID: 33034437
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
[TBL] [Abstract][Full Text] [Related]
28. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis.
Chandran V; Gottlieb A; Cook RJ; Duffin KC; Garg A; Helliwell P; Kavanaugh A; Krueger GG; Langley RG; Lynde C; McHugh N; Mease P; Olivieri I; Rahman P; Rosen CF; Salvarani C; Thaci D; Toloza SM; Wong MY; Zhou QM; Gladman DD
Arthritis Rheum; 2009 Sep; 61(9):1235-42. PubMed ID: 19714610
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
30. Certolizumab pegol for the treatment of psoriasis.
Campanati A; Benfaremo D; Luchetti MM; Ganzetti G; Gabrielli A; Offidani A
Expert Opin Biol Ther; 2017 Mar; 17(3):387-394. PubMed ID: 28165828
[TBL] [Abstract][Full Text] [Related]
31. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
Kavanaugh A; McInnes IB; Krueger GG; Gladman D; Beutler A; Gathany T; Mack M; Tandon N; Han C; Mease P
Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608
[TBL] [Abstract][Full Text] [Related]
32. Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.
Umezawa Y; Sakurai S; Hoshii N; Nakagawa H;
Dermatol Ther (Heidelb); 2021 Apr; 11(2):513-528. PubMed ID: 33606269
[TBL] [Abstract][Full Text] [Related]
33. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
Warren RB; Lebwohl M; Sofen H; Piguet V; Augustin M; Brock F; C Arendt ; Fierens F; Blauvelt A
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2398-2408. PubMed ID: 34192387
[TBL] [Abstract][Full Text] [Related]
34. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.
Griffiths CE; Sterry W; Brock F; Dilleen M; Stefanidis D; Germain JM; Mallbris L
Br J Dermatol; 2015 Jan; 172(1):230-8. PubMed ID: 24861696
[TBL] [Abstract][Full Text] [Related]
35. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.
Mease P; Deodhar A; Fleischmann R; Wollenhaupt J; Gladman D; Leszczyński P; Vitek P; Turkiewicz A; Khraishi M; FitzGerald O; Landewé R; de Longueville M; Hoepken B; Peterson L; van der Heijde D
RMD Open; 2015; 1(1):e000119. PubMed ID: 26509074
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
37. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
[TBL] [Abstract][Full Text] [Related]
39. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
Merola JF; Papp KA; Nash P; Gratacós J; Boehncke WH; Thaçi D; Graham D; Hsu MA; Wang C; Wu J; Young P
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2809-2820. PubMed ID: 32271970
[TBL] [Abstract][Full Text] [Related]
40. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.
Nash P; Thaçi D; Behrens F; Falk F; Kaltwasser JP
Dermatology; 2006; 212(3):238-49. PubMed ID: 16549920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]